Harvey Slusky, MD
Cardiology · Webster, TXNPI 1700816790
Payments from drug & device makers
What this record shows
This record is dominated by other: $22,459 of the $26,298 with a category attached, or 85.4%. Medtronic accounts for 96.1% of it on its own, with 16 other manufacturers making up the rest. 2024 is the largest year on record at $22,741, more than ten times the $127 reported in 2019. Among cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $328.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$25K
- Medicure Pharma Inc.$120
- Abbott$112
- Johnson & Johnson$110
- Venclose Inc.$107
- Amgen$85
- plus $493 from 11 others
What the payments were for
- Travel & lodging$1,5346%
- Food & beverage$2,3069%
- Other$22,45985%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 32 | $25,273 |
| Medicure Pharma Inc. | 1 | $120 |
| Abbott | 7 | $112 |
| Johnson & Johnson | 6 | $110 |
| Venclose Inc. | 6 | $107 |
| Amgen | 4 | $85 |
| Bard Peripheral Vascular, Inc. | 5 | $81 |
| Pfizer | 3 | $80 |
| Boston Scientific | 3 | $72 |
| AstraZeneca | 3 | $53 |
| Boehringer Ingelheim | 2 | $49 |
| Inspire Medical Systems, Inc. | 1 | $38 |
| Bardy Diagnostics, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Avinger Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $21 |
| Abiomed | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,298 in reported general payments places this provider in the 95th percentile of 33 cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 192 | $199,908 |
| XareltoRivaroxaban | 145 | $129,314 |
| Praluent PenAlirocumab | 11 | $14,112 |
| BrilintaTicagrelor | 12 | $13,910 |
| Repatha PushtronexEvolocumab | 12 | $12,669 |
| Repatha SureclickEvolocumab | 11 | $11,860 |
| JardianceEmpagliflozin | 13 | $9,907 |
| EntrestoSacubitril/Valsartan | 11 | $7,514 |
| Clonidine | 37 | $4,661 |
| Ranolazine ErRanolazine | 24 | $4,506 |
| Metoprolol Succinate | 228 | $3,865 |
| Atorvastatin Calcium | 311 | $2,885 |
| Prasugrel Hcl | 28 | $2,853 |
| Nebivolol Hcl | 45 | $2,596 |
| Valsartan | 89 | $2,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $199,908192 claims |
| Johnson & JohnsonXarelto | $110 | $129,314145 claims |
| AstraZenecaBrilinta | $53 | $13,91012 claims |
| Boehringer IngelheimJardiance | $49 | $9,90713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 cardiology providers in Texas.
Other cardiology in Webster
- Nadir AliWebster$3K
- Shiny MathewkuttyDallas$24K
- Sheikh AhmedHouston$14K
- Lane MillerCollege Station$11K
- Ramon TyHouston$11K
- Faizan IftikharMcKinney$7K
- Thieu NguyenHouston$5K
- Nadim ZaccaHouston$2K
- Adeniran AriyoDallas$1K
- Ralph NimchanLaredo$702
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.